US · PFSA
Profusa, Inc. Common Stock
- Sector
- Healthcare · Medical - Equipment & Services
- Headquarters
- EmeryVille, CA 94608
- Website
- profusa.com
Price · as of 2024-12-31
$0.56
Market cap 579.06K
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 |
AI valuation
Our deep-learning model estimates Profusa, Inc. Common Stock's (PFSA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.56
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PFSA | Profusa, Inc. Common Stoc… | $0.56 | 579.06K | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | 8.05% | 6.39% | -371.73% | -0.40 | -1.02 | 0.00 | 0.00 | -9.99 | -968.00% | — | -5309.00% | — | -0.04 | 2.93% | — | 0.00% | — | — | — | — | — |
| ACXP | Acurx Pharmaceuticals, In… | $1.50 | 2.38M | — | — | — | — | -0.55 | 12.65 | — | — | — | 12.65 | 0.00% | — | — | -534.03% | 478.14% | -243.85% | 0.00 | — | 1.19 | 1.16 | — | -2355.00% | — | 594.00% | -133.41% | -3.20 | 352.03% | 0.00% | 0.00% | 0.00% | -0.29 | -0.39 | — | -34.86 |
| ADIL | Adial Pharmaceuticals, In… | $2.53 | 2.43M | — | — | — | — | -1.06 | 3.43 | — | -1.23 | — | 3.43 | 0.00% | — | — | -323.80% | -1052.66% | -269.86% | 0.00 | — | 4.16 | 3.84 | 0.45 | -8695.00% | — | — | -49.65% | -7.09 | -879.58% | 0.00% | 0.00% | 6.62% | -1.23 | -1.47 | — | -18.87 |
| APRE | Aprea Therapeutics, Inc. | $0.92 | 6.41M | +3,789% | +73% | — | — | -0.99 | 0.66 | 8.54 | 0.70 | — | 0.66 | -523.16% | -953.00% | -862.43% | -68.98% | 415.99% | -55.58% | 0.00 | — | 7.01 | 6.80 | 1.60 | -4051.00% | 15763.00% | 1061.00% | -105.72% | -4.03 | 394.27% | 0.00% | 0.00% | 9.68% | 0.70 | 0.74 | -6.66 | -17.99 |
| BCDA | BioCardia, Inc. | $1.29 | 7.48M | +6,369% | -19% | — | +16,927% | -0.90 | 8.59 | 123.95 | -0.73 | — | 8.59 | -7463.79% | -13794.83% | -13700.00% | 2074.67% | 810.64% | -236.81% | 1.14 | — | 1.13 | 1.02 | 0.18 | -6459.00% | -8784.00% | -1957.00% | -111.72% | -3.46 | 813.78% | 0.00% | 0.00% | 22.70% | -0.72 | -0.72 | 99.47 | -65.68 |
| BFRI | Biofrontera Inc. | $0.91 | 10.62M | +16,739% | -59% | — | — | -0.29 | 1.14 | 0.14 | -0.28 | — | 1.15 | 50.12% | -46.14% | -47.61% | -384.98% | -281.81% | -70.99% | 1.11 | -8.17 | 1.72 | 0.93 | 0.07 | -7527.00% | 949.00% | -5851.00% | -203.55% | -0.85 | -169.15% | 0.00% | 0.00% | 99.29% | -0.24 | -0.40 | 0.11 | -7.68 |
| CHEK | Check-Cap Ltd. | $1.68 | 9.83M | — | — | — | — | -0.19 | -3.24 | — | -0.49 | -0.43 | -3.24 | 0.00% | — | — | -226.19% | 1959.89% | -198.07% | -0.09 | -2883.22 | 0.15 | 0.15 | -0.01 | 4333.00% | — | -9995.00% | -0.17% | 0.00 | 0.60% | 0.00% | 0.00% | 0.00% | -0.18 | -570.68 | — | -861.86 |
| HCWB | HCW Biologics Inc. | $0.54 | 1.16M | +6,101% | +980% | — | +51% | -18.86 | -83.66 | 220.66 | -20.79 | -188.64 | -83.66 | 37.38% | -1148.50% | -1169.70% | -897.37% | -320.11% | -102.21% | -2.02 | -25.45 | 0.19 | 0.18 | -0.33 | 1000.00% | -968.00% | -4954.00% | -2.56% | -0.48 | -157.33% | 0.00% | 0.00% | 0.00% | -19.52 | -39.71 | 224.17 | 0.44 |
| LUCY | Innovative Eyewear, Inc. | $1.12 | 5.12M | +2,253% | +40,227,901% | — | — | -0.81 | 0.69 | 3.84 | 0.16 | — | 0.73 | 13.15% | -484.20% | -474.60% | -106.00% | -557.55% | -96.74% | 0.00 | — | 12.52 | 10.38 | 0.35 | -5904.00% | 4199.00% | 1643.00% | -111.49% | -9.14 | -493.01% | 0.00% | 0.00% | 0.00% | 0.16 | 0.18 | -0.76 | 0.10 |
| SBFM | Sunshine Biopharma, Inc. | $1.20 | 5.89M | +4,340% | +64,945,046% | — | — | -0.33 | 0.07 | 0.05 | 1.37 | — | 0.08 | 30.60% | -16.67% | -14.72% | -22.97% | -54.65% | -17.73% | 0.04 | -662.41 | 4.11 | 2.15 | 1.69 | -9792.00% | 4475.00% | 5530.00% | -885.54% | -1.98 | -146.04% | 0.00% | 0.00% | 187.20% | 1.21 | 0.48 | -0.20 | -1.74 |
About Profusa, Inc. Common Stock
A digital-health company developing tissue-integrating biosensors (e.g. the Lumee™ Oxygen Platform) to continuously monitor body chemistry and provide AI-powered health insights, targeting chronic conditions such as diabetes and critical limb ischemia
- CEO
- Ben Chung-Bin Hwang
- Employees
- 2
- Beta
- -0.16
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.56) − 1 = — (DCF, example).